Literature DB >> 1383899

Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein.

C Zelop1, A Nadel, F D Frigoletto, S Pauker, M MacMillan, B R Benacerraf.   

Abstract

OBJECTIVE: To investigate the relationship between elevated maternal serum alpha-fetoprotein (MSAFP) and abnormal placental adherence (placenta accreta/percreta/increta).
METHODS: We reviewed the MSAFP levels of 11 women who had cesarean hysterectomies because of placenta accreta/percreta/increta. The control group consisted of 14 women who delivered by cesarean because of placenta previa but who had no abnormal placental adherence.
RESULTS: Five of the 11 women with placenta accreta/percreta/increta had elevated MSAFP, whereas all 14 controls had normal levels.
CONCLUSION: These results indicate a significant association between elevated MSAFP and placenta accreta/percreta/increta (P = .017). Patients with an unexplained elevation of MSAFP as well as placenta previa may be at increased risk for abnormal placental adherence.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1383899

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  10 in total

1.  Cocooned by complications: fetal survival through placental adherence.

Authors:  Deepa Balachandran Nair; Marion Beard; Franz Majoko
Journal:  BMJ Case Rep       Date:  2016-06-29

2.  Maternal serum markers, characteristics and morbidly adherent placenta in women with previa.

Authors:  D J Lyell; A M Faucett; R J Baer; Y J Blumenfeld; M L Druzin; Y Y El-Sayed; G M Shaw; R J Currier; L L Jelliffe-Pawlowski
Journal:  J Perinatol       Date:  2015-04-30       Impact factor: 2.521

Review 3.  First trimester serum PAPP-A is associated with placenta accreta: a retrospective study.

Authors:  Fengge Wang; Shuxiong Chen; Jishui Wang; Yangping Wang; Fang Ruan; Hua Shu; Liangxi Zhu; Dongmei Man
Journal:  Arch Gynecol Obstet       Date:  2021-01-30       Impact factor: 2.344

4.  Increased levels of cell-free human placental lactogen mRNA at 28-32 gestational weeks in plasma of pregnant women with placenta previa and invasive placenta.

Authors:  Akihiro Kawashima; Akihiko Sekizawa; Walter Ventura; Keiko Koide; Kyouko Hori; Takashi Okai; Yoshida Masashi; Kenichi Furuya; Yoshifumi Mizumoto
Journal:  Reprod Sci       Date:  2013-06-06       Impact factor: 3.060

5.  Mid-trimester maternal serum HCG and alpha fetal protein levels: clinical significance and prediction of adverse pregnancy outcome.

Authors:  Georgios Androutsopoulos; Panagiotis Gkogkos; Georgios Decavalas
Journal:  Int J Endocrinol Metab       Date:  2013-04-01

6.  Conservative management of placenta accreta in a multiparous woman.

Authors:  Jennifer C Hunt
Journal:  J Pregnancy       Date:  2010-09-30

7.  Epidemiology, etiology, diagnosis, and management of placenta accreta.

Authors:  Gali Garmi; Raed Salim
Journal:  Obstet Gynecol Int       Date:  2012-05-07

8.  Giants in Obstetrics and Gynecology Series: a profile of Beryl Benacerraf, MD.

Authors:  Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2021-04-03       Impact factor: 10.693

Review 9.  Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers.

Authors:  Helena C Bartels; James D Postle; Paul Downey; Donal J Brennan
Journal:  Dis Markers       Date:  2018-07-03       Impact factor: 3.434

Review 10.  Maternal Serum Screening Markers and Adverse Outcome: A New Perspective.

Authors:  David Krantz; Terrence Hallahan; David Janik; Jonathan Carmichael
Journal:  J Clin Med       Date:  2014-07-03       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.